Literature DB >> 12112734

The phenotypic consequences of MECP2 mutations extend beyond Rett syndrome.

Sara Hammer1, Naghmeh Dorrani, Joanna Dragich, Shinichi Kudo, Carolyn Schanen.   

Abstract

Although MECP2 was initially identified as the causative gene in classic Rett syndrome (RTT), the gene has now been implicated in several phenotypes that extend well beyond the clinically defined disorder. MECP2 mutations have been found in people with various disorders, including neonatal onset encephalopathy, X-linked recessive mental retardation (MRX), classic and atypical RTT, autism, and Angelman syndrome, as well as mildly affected females and normal carrier females. To make matters more complex, in approximately 20% of classic sporadic RTT cases and more than 50% of affected sister pairs, no mutation in MECP2 has been found. X-chromosome inactivation patterns can clearly affect the phenotypic expression in females, while the effect of the type and position of the mutation is more apparent in the broader phenotype than in RTT. Both males and females are at risk, although an excess of paternally derived mutations are found in most cases of classic RTT. Thus, because of the range of disparate phenotypes, the gene may account for a relatively large portion of mental retardation in the population. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112734     DOI: 10.1002/mrdd.10023

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  17 in total

Review 1.  The neurobiology of autism: new pieces of the puzzle.

Authors:  Maria T Acosta; Phillip L Pearl
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells.

Authors:  Maria C N Marchetto; Cassiano Carromeu; Allan Acab; Diana Yu; Gene W Yeo; Yangling Mu; Gong Chen; Fred H Gage; Alysson R Muotri
Journal:  Cell       Date:  2010-11-12       Impact factor: 41.582

Review 3.  Evolving role of MeCP2 in Rett syndrome and autism.

Authors:  Janine M LaSalle; Dag H Yasui
Journal:  Epigenomics       Date:  2009-10       Impact factor: 4.778

4.  Applying the ethoexperimental approach to neurodevelopmental syndrome research reveals exaggerated defensive behavior in Mecp2 mutant mice.

Authors:  Brandon L Pearson; Erwin B Defensor; D Caroline Blanchard; Robert J Blanchard
Journal:  Physiol Behav       Date:  2015-07-01

5.  Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2.

Authors:  Juan I Young; Eugene P Hong; John C Castle; Juan Crespo-Barreto; Aaron B Bowman; Matthew F Rose; Dongcheul Kang; Ron Richman; Jason M Johnson; Susan Berget; Huda Y Zoghbi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-26       Impact factor: 11.205

Review 6.  A review of Rett syndrome (RTT) with induced pluripotent stem cells.

Authors:  Vellingiri Balachandar; Venkatesan Dhivya; Mohan Gomathi; Subramaniam Mohanadevi; Balasubramanian Venkatesh; Bharathi Geetha
Journal:  Stem Cell Investig       Date:  2016-09-28

7.  Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain.

Authors:  S Kudo; Y Nomura; M Segawa; N Fujita; M Nakao; C Schanen; M Tamura
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

8.  X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of rett syndrome.

Authors:  Juan I Young; Huda Y Zoghbi
Journal:  Am J Hum Genet       Date:  2004-02-17       Impact factor: 11.025

Review 9.  The role of MeCP2 in brain development and neurodevelopmental disorders.

Authors:  Michael L Gonzales; Janine M LaSalle
Journal:  Curr Psychiatry Rep       Date:  2010-04       Impact factor: 5.285

10.  Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation.

Authors:  Raman P Nagarajan; Amber R Hogart; Ynnez Gwye; Michelle R Martin; Janine M LaSalle
Journal:  Epigenetics       Date:  2006 Oct-Dec       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.